Gina Consylman Sells 1,510 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Stock

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) CFO Gina Consylman sold 1,510 shares of the company’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $11.00, for a total transaction of $16,610.00. Following the completion of the sale, the chief financial officer now directly owns 174,768 shares of the company’s stock, valued at approximately $1,922,448. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Gina Consylman also recently made the following trade(s):

  • On Friday, August 16th, Gina Consylman sold 212 shares of Ironwood Pharmaceuticals stock. The shares were sold at an average price of $9.04, for a total transaction of $1,916.48.

IRWD traded up $0.07 during trading on Thursday, hitting $11.45. 19,100 shares of the stock traded hands, compared to its average volume of 1,272,481. The firm has a market capitalization of $1.74 billion, a P/E ratio of -11.97 and a beta of 1.80. The firm has a 50-day moving average of $9.35 and a 200 day moving average of $10.07. Ironwood Pharmaceuticals, Inc. has a 12-month low of $7.91 and a 12-month high of $15.21.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings results on Thursday, October 31st. The biotechnology company reported $0.40 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.10 by $0.30. The business had revenue of $131.17 million during the quarter, compared to analysts’ expectations of $97.10 million. Ironwood Pharmaceuticals had a negative net margin of 9.67% and a negative return on equity of 15.83%. The firm’s revenue for the quarter was up 99.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.27) EPS. As a group, equities research analysts expect that Ironwood Pharmaceuticals, Inc. will post 0.49 EPS for the current fiscal year.

A number of equities research analysts have recently issued reports on the stock. ValuEngine cut shares of Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. BidaskClub raised shares of Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, November 8th. Cowen set a $12.00 price objective on shares of Ironwood Pharmaceuticals and gave the company a “hold” rating in a research note on Friday, September 13th. Finally, Wedbush upped their price objective on shares of Ironwood Pharmaceuticals from $11.00 to $12.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Nine equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Ironwood Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $14.50.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Signition LP purchased a new stake in Ironwood Pharmaceuticals during the 3rd quarter valued at $100,000. Grimes & Company Inc. purchased a new stake in Ironwood Pharmaceuticals during the 3rd quarter valued at $147,000. California Public Employees Retirement System boosted its position in Ironwood Pharmaceuticals by 23.7% during the 3rd quarter. California Public Employees Retirement System now owns 284,642 shares of the biotechnology company’s stock valued at $2,444,000 after buying an additional 54,536 shares during the period. Diamond Hill Capital Management Inc. boosted its position in Ironwood Pharmaceuticals by 95.1% during the 3rd quarter. Diamond Hill Capital Management Inc. now owns 20,512 shares of the biotechnology company’s stock valued at $176,000 after buying an additional 10,000 shares during the period. Finally, First Quadrant L P CA purchased a new stake in Ironwood Pharmaceuticals during the 3rd quarter valued at $358,000.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD.

Recommended Story: Compound Interest and Why It Matters When Investing

Insider Buying and Selling by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.